Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
Amedeo Lonardo, Fabio Nascimbeni, Stefano Ballestri, et al.
Hepatology (2019) Vol. 70, Iss. 4, pp. 1457-1469
Open Access | Times Cited: 737

Showing 1-25 of 737 citing articles:

MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
Mohammed Eslam, Arun J. Sanyal, Jacob George, et al.
Gastroenterology (2020) Vol. 158, Iss. 7, pp. 1999-2014.e1
Open Access | Times Cited: 2633
Sex and gender: modifiers of health, disease, and medicine
Franck Mauvais‐Jarvis, C. Noel Bairey Merz, Peter J. Barnes, et al.
The Lancet (2020) Vol. 396, Iss. 10250, pp. 565-582
Open Access | Times Cited: 1476
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
Kiarash Riazi, Hassan Azhari, Jacob H Charette, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 7, Iss. 9, pp. 851-861
Closed Access | Times Cited: 1339
Sex differences in metabolic regulation and diabetes susceptibility
Blandine Tramunt, Sarra Smati, Naia Grandgeorge, et al.
Diabetologia (2019) Vol. 63, Iss. 3, pp. 453-461
Open Access | Times Cited: 651
NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications
Giovanni Targher, Christopher D. Byrne, Herbert Tilg
Gut (2020) Vol. 69, Iss. 9, pp. 1691-1705
Open Access | Times Cited: 587
Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 70, Iss. 5, pp. 962-969
Open Access | Times Cited: 360
Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
Gopanandan Parthasarathy, Xavier S. Revelo, Harmeet Malhi
Hepatology Communications (2020) Vol. 4, Iss. 4, pp. 478-492
Open Access | Times Cited: 349
Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
Daniel Ferguson, Brian N. Finck
Nature Reviews Endocrinology (2021) Vol. 17, Iss. 8, pp. 484-495
Open Access | Times Cited: 340
Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Gut (2020) Vol. 71, Iss. 1, pp. 156-162
Open Access | Times Cited: 265
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani, Graziana Petracca, Giorgia Beatrice, et al.
Metabolites (2021) Vol. 11, Iss. 2, pp. 73-73
Open Access | Times Cited: 219
Current status and future trends of the global burden of MASLD
Lei Miao, Giovanni Targher, Christopher D. Byrne, et al.
Trends in Endocrinology and Metabolism (2024) Vol. 35, Iss. 8, pp. 697-707
Closed Access | Times Cited: 214
NAFLD and NASH in Postmenopausal Women: Implications for Diagnosis and Treatment
Johanna K. DiStefano
Endocrinology (2020) Vol. 161, Iss. 10
Open Access | Times Cited: 163
Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Soo Lim, Jin‐Wook Kim, Giovanni Targher
Trends in Endocrinology and Metabolism (2021) Vol. 32, Iss. 7, pp. 500-514
Closed Access | Times Cited: 151
Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study
Shuai Yuan, Jie Chen, Xue Li, et al.
European Journal of Epidemiology (2022) Vol. 37, Iss. 7, pp. 723-733
Open Access | Times Cited: 131
Clinical impact of sexual dimorphism in non‐alcoholic fatty liver disease (NAFLD) and non‐alcoholic steatohepatitis (NASH)
Patrizia Burra, Debora Bizzaro, Anna Gonta, et al.
Liver International (2021) Vol. 41, Iss. 8, pp. 1713-1733
Open Access | Times Cited: 117
A researcher’s guide to preclinical mouse NASH models
Suchira Gallage, Jose Efren Barragan Avila, Pierluigi Ramadori, et al.
Nature Metabolism (2022) Vol. 4, Iss. 12, pp. 1632-1649
Closed Access | Times Cited: 111
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors
Emir Muzurović, Carol Chiung‐Hui Peng, Matthew J. Belanger, et al.
Hypertension (2022) Vol. 79, Iss. 7, pp. 1319-1326
Closed Access | Times Cited: 89
Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice
Qian Ye, Yi Liu, Guiji Zhang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 76
Western diet contributes to the pathogenesis of non-alcoholic steatohepatitis in male mice via remodeling gut microbiota and increasing production of 2-oleoylglycerol
Ming Yang, Xiaoqiang Qi, Nan Li, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 58
Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019
Xiaoning Wu, Feng Xue, Nan Zhang, et al.
BMC Public Health (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 47
Associations between dietary flavonoid intake with hepatic steatosis and fibrosis quantified by VCTE: Evidence from NHANES and FNDDS
Ruijie Xie, Ya Zhang
Nutrition Metabolism and Cardiovascular Diseases (2023) Vol. 33, Iss. 6, pp. 1179-1189
Closed Access | Times Cited: 44
Outcomes of Various Classes of Oral Antidiabetic Drugs on Nonalcoholic Fatty Liver Disease
Heejoon Jang, Yeonjin Kim, Dong Hyeon Lee, et al.
JAMA Internal Medicine (2024) Vol. 184, Iss. 4, pp. 375-375
Closed Access | Times Cited: 39
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Maximilian Huttasch, Michael Roden, S. Kahl
Metabolism (2024) Vol. 157, pp. 155937-155937
Open Access | Times Cited: 37
Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries
Ehsan Amini‐Salehi, Negin Letafatkar, Naeim Norouzi, et al.
Archives of Medical Research (2024) Vol. 55, Iss. 6, pp. 103043-103043
Closed Access | Times Cited: 37
Insights and implications of sexual dimorphism in osteoporosis
Yuanyuan Zhang, Na Xie, Xiaodong Sun, et al.
Bone Research (2024) Vol. 12, Iss. 1
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top